{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360298760973190656.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1136/jitc-2020-002231"}},{"identifier":{"@type":"URI","@value":"https://syndication.highwire.org/content/doi/10.1136/jitc-2020-002231"}}],"dc:title":[{"@value":"Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:sec>\n                  <jats:title>Background</jats:title>\n                  <jats:p>CD8+ tissue-resident memory T (T<jats:sub>RM</jats:sub>) cells, marked by CD103 (<jats:italic>ITGAE</jats:italic>) expression, are thought to actively suppress cancer progression, leading to the hypothesis that their presence in tumors may predict response to immunotherapy.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Methods</jats:title>\n                  <jats:p>Here, we test this by combining high-dimensional single-cell modalities with bulk tumor transcriptomics from 1868 patients enrolled in lung and bladder cancer clinical trials of atezolizumab (anti-programmed cell death ligand 1 (PD-L1)).</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Results</jats:title>\n                  <jats:p>\n                     <jats:italic>ITGAE</jats:italic> was identified as the most significantly upregulated gene in inflamed tumors. Tumor CD103+ CD8+ T<jats:sub>RM</jats:sub> cells exhibited a complex phenotype defined by the expression of checkpoint regulators, cytotoxic proteins, and increased clonal expansion.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions</jats:title>\n                  <jats:p>Our analyses indeed demonstrate that the presence of CD103+ CD8+ T<jats:sub>RM</jats:sub> cells, quantified by tracking intratumoral CD103 expression, can predict treatment outcome, suggesting that patients who respond to PD-1/PD-L1 blockade are those who exhibit an ongoing antitumor T-cell response.</jats:p>\n               </jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380298760973190666","@type":"Researcher","foaf:name":[{"@value":"Romain Banchereau"}],"jpcoar:affiliationName":[{"@value":"Department of Oncology Biomarker Development, Genentech Inc, South San Francisco, California, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298760973190660","@type":"Researcher","foaf:name":[{"@value":"Avantika S. Chitre"}],"jpcoar:affiliationName":[{"@value":"Department of Cancer Immunology, Genentech Inc, South San Francisco, California, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298760973190668","@type":"Researcher","foaf:name":[{"@value":"Alexis Scherl"}],"jpcoar:affiliationName":[{"@value":"Department of Research Pathology, Genentech Inc, South San Francisco, California, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298760973190669","@type":"Researcher","foaf:name":[{"@value":"Thomas D. Wu"}],"jpcoar:affiliationName":[{"@value":"Department of Bioinformatics and Computational Biology, Genentech Inc, South San Francisco, California, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298760973190664","@type":"Researcher","foaf:name":[{"@value":"Namrata S. Patil"}],"jpcoar:affiliationName":[{"@value":"Department of Oncology Biomarker Development, Genentech Inc, South San Francisco, California, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298760973190659","@type":"Researcher","foaf:name":[{"@value":"Patricia de Almeida"}],"jpcoar:affiliationName":[{"@value":"Department of Cancer Immunology, Genentech Inc, South San Francisco, California, USA"},{"@value":"Adaptive Biotechnologies Corp South San Francisco, South San Francisco, California, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298760973190676","@type":"Researcher","foaf:name":[{"@value":"Edward E. Kadel, III"}],"jpcoar:affiliationName":[{"@value":"Department of Oncology Biomarker Development, Genentech Inc, South San Francisco, California, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298760973190672","@type":"Researcher","foaf:name":[{"@value":"Shravan Madireddi"}],"jpcoar:affiliationName":[{"@value":"Department of Cancer Immunology, Genentech Inc, South San Francisco, California, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298760973190679","@type":"Researcher","foaf:name":[{"@value":"Amelia Au-Yeung"}],"jpcoar:affiliationName":[{"@value":"Department of OMNI Biomarker Development, Genentech Inc, South San Francisco, California, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298760973190671","@type":"Researcher","foaf:name":[{"@value":"Chikara Takahashi"}],"jpcoar:affiliationName":[{"@value":"Department of OMNI Biomarker Development, Genentech Inc, South San Francisco, California, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298760973190677","@type":"Researcher","foaf:name":[{"@value":"Ying-Jiun Chen"}],"jpcoar:affiliationName":[{"@value":"Department of Microchemistry, Proteomics, Lipidomics, and Next Generation Sequencing, Genentech Inc, South San Francisco, California, USA"},{"@value":"Analytical Biosciences Limited, South San Francisco, California, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298760973190681","@type":"Researcher","foaf:name":[{"@value":"Zora Modrusan"}],"jpcoar:affiliationName":[{"@value":"Department of Microchemistry, Proteomics, Lipidomics, and Next Generation Sequencing, Genentech Inc, South San Francisco, California, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298760973190673","@type":"Researcher","foaf:name":[{"@value":"Jacqueline McBride"}],"jpcoar:affiliationName":[{"@value":"Department of OMNI Biomarker Development, Genentech Inc, South San Francisco, California, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298760973190661","@type":"Researcher","foaf:name":[{"@value":"Rhea Nersesian"}],"jpcoar:affiliationName":[{"@value":"Department of Oncology Biomarker Development, Genentech Inc, South San Francisco, California, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298760973190674","@type":"Researcher","foaf:name":[{"@value":"Ehab A. El-Gabry"}],"jpcoar:affiliationName":[{"@value":"Ventana Medical Systems Inc, Tucson, Arizona, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298760973190665","@type":"Researcher","foaf:name":[{"@value":"Mark D. Robida"}],"jpcoar:affiliationName":[{"@value":"Ventana Medical Systems Inc, Tucson, Arizona, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298760973190529","@type":"Researcher","foaf:name":[{"@value":"Jeffrey C. Hung"}],"jpcoar:affiliationName":[{"@value":"Department of Research Pathology, Genentech Inc, South San Francisco, California, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298760973190662","@type":"Researcher","foaf:name":[{"@value":"Marcin Kowanetz"}],"jpcoar:affiliationName":[{"@value":"Department of Oncology Biomarker Development, Genentech Inc, South San Francisco, California, USA"},{"@value":"Bolt Biotherapeutics, Redwood City, California, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298760973190658","@type":"Researcher","foaf:name":[{"@value":"Wei Zou"}],"jpcoar:affiliationName":[{"@value":"Department of Biostatistics Oncology, Genentech Inc, South San Francisco, California, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298760973190682","@type":"Researcher","foaf:name":[{"@value":"Mark McCleland"}],"jpcoar:affiliationName":[{"@value":"Department of Oncology Biomarker Development, Genentech Inc, South San Francisco, California, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298760973190678","@type":"Researcher","foaf:name":[{"@value":"Patrick Caplazi"}],"jpcoar:affiliationName":[{"@value":"Department of Research Pathology, Genentech Inc, South San Francisco, California, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298760973190656","@type":"Researcher","foaf:name":[{"@value":"Shadi Toghi Eshgi"}],"jpcoar:affiliationName":[{"@value":"Department of OMNI Biomarker Development, Genentech Inc, South San Francisco, California, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298760973190663","@type":"Researcher","foaf:name":[{"@value":"Hartmut Koeppen"}],"jpcoar:affiliationName":[{"@value":"Department of Research Pathology, Genentech Inc, South San Francisco, California, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298760973190657","@type":"Researcher","foaf:name":[{"@value":"Priti S. Hegde"}],"jpcoar:affiliationName":[{"@value":"Foundation Medicine, Cambridge, Massachusetts, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298760973190667","@type":"Researcher","foaf:name":[{"@value":"Ira Mellman"}],"jpcoar:affiliationName":[{"@value":"Department of Cancer Immunology, Genentech Inc, South San Francisco, California, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298760973190670","@type":"Researcher","foaf:name":[{"@value":"W. Rodney Mathews"}],"jpcoar:affiliationName":[{"@value":"Department of OMNI Biomarker Development, Genentech Inc, South San Francisco, California, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298760973190675","@type":"Researcher","foaf:name":[{"@value":"Thomas Powles"}],"jpcoar:affiliationName":[{"@value":"Barts Cancer Center, Queen Mary University, London, UK"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298760973190680","@type":"Researcher","foaf:name":[{"@value":"Sanjeev Mariathasan"}],"jpcoar:affiliationName":[{"@value":"Department of Oncology Biomarker Development, Genentech Inc, South San Francisco, California, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298760973190683","@type":"Researcher","foaf:name":[{"@value":"Jane Grogan"}],"jpcoar:affiliationName":[{"@value":"Department of Cancer Immunology, Genentech Inc, South San Francisco, California, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298760973190528","@type":"Researcher","foaf:name":[{"@value":"William E O'Gorman"}],"jpcoar:affiliationName":[{"@value":"Department of OMNI Biomarker Development, Genentech Inc, South San Francisco, California, USA"}]}],"publication":{"publicationIdentifier":[{"@type":"EISSN","@value":"20511426"}],"prism:publicationName":[{"@value":"Journal for ImmunoTherapy of Cancer"}],"dc:publisher":[{"@value":"BMJ"}],"prism:publicationDate":"2021-04","prism:volume":"9","prism:number":"4","prism:startingPage":"e002231"},"reviewed":"false","dc:rights":["http://creativecommons.org/licenses/by-nc/4.0/"],"url":[{"@id":"https://syndication.highwire.org/content/doi/10.1136/jitc-2020-002231"}],"createdAt":"2021-04-07","modifiedAt":"2025-10-03","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360025431097219456","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The emerging role of effector functions exerted by tissue-resident memory T cells"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861707396716288","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Fundamental and Essential Knowledge for Pathologists Engaged in the Research and Practice of Immune Checkpoint Inhibitor-Based Cancer Immunotherapy"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1136/jitc-2020-002231"},{"@type":"CROSSREF","@value":"10.1093/oxfimm/iqae006_references_DOI_FKVn7gjA4iQ0nlc9SGfLdPQ3fJj"},{"@type":"CROSSREF","@value":"10.3389/fonc.2021.679095_references_DOI_FKVn7gjA4iQ0nlc9SGfLdPQ3fJj"}]}